US2023346846A1PendingUtilityA1

Method of treating graft versus hot disease

84
Assignee: MESOBLAST INCPriority: Jul 2, 2010Filed: Mar 29, 2023Published: Nov 2, 2023
Est. expiryJul 2, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Silviu ItescuMichael Schuster
A61K 35/28C12N 5/0663A61P 37/02A61K 2035/122A61P 37/06A61K 45/06
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright cells and/or progeny thereof and/or soluble factors derived therefrom.

Claims

exact text as granted — not AI-modified
1 . A method for preventing the development of or treating GvHD complications in a patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright  cells and/or progeny thereof. 
     
     
         2 . A method for preventing the development of or treating GvHD complications in a patient which comprises administering to the mammal a population of cells enriched for STRO-1 bright  cells and/or progeny thereof. 
     
     
         3 . The method according to  claim 2 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered to the patient prior to administration of the precursors of bone marrow lineage cells. 
     
     
         4 . The method according to  claim 2 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is co-administered with the precursors of bone marrow lineage cells. 
     
     
         5 . The method according to  claim 2 , wherein the precursors of bone marrow lineage cells are allogeneic cells administered to the mammal to treat a malignant or genetic disease of the blood. 
     
     
         6 . The method according to  claim 1  wherein the STRO-1 bright  cells and/or progeny thereof are allogeneic. 
     
     
         7 . The method according to  claim 1  wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered systemically. 
     
     
         8 . The method according to  claim 7 , wherein the population of cells enriched for STRO-1 bright  cells and/or progeny cells thereof is administered by intravenous injection. 
     
     
         9 . The method of  claim 1 , comprising administering from 0.1×10 6  to 5×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         10 . The method of  claim 1 , comprising administering from 0.3×10 6  to 2×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         11 . The method of  claim 1  comprising administering a low dose of STRO-1 bright  cells and/or progeny thereof. 
     
     
         12 . The method of  claim 11 , wherein the low dose of STRO-1 bright  cells and/or progeny thereof comprises between 0.1×10 5  and 0.5×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         13 . The method of  claim 11 , wherein the low dose of STRO-1 bright  cells and/or progeny thereof comprises about 0.3×10 6  STRO-1 bright  cells and/or progeny thereof. 
     
     
         14 . The method of  claim 1 , wherein the population enriched for STRO-1 bright  cells and/or progeny thereof is administered once weekly or less often. 
     
     
         15 . The method according to  claim 1 , wherein the mammal is suffering from aplastic anemia, myelofibrosis, or bone marrow failure following chemotherapy and radiation therapy. 
     
     
         16 . The method according to  claim 1 , further comprising administering an immunosuppressive drug to the mammal.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.